NeOnc Technologies Holdings, Inc. Common Stock (NTHI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NeOnc Technologies Holdings, Inc. Common Stock (NTHI) has a cash flow conversion efficiency ratio of 0.528x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.99 Million) by net assets ($-13.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NTHI net asset quality score to measure how much of total assets are equity-financed.
NeOnc Technologies Holdings, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NTHI capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
NeOnc Technologies Holdings, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeOnc Technologies Holdings, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adocia
PA:ADOC
|
1.826x |
|
Kencana Agri Limited
F:KEBA
|
0.269x |
|
Consti Yhtiot Oy
HE:CONSTI
|
0.227x |
|
Krystal Integrated Services Ltd
NSE:KRYSTAL
|
-0.026x |
|
Bionet
TWO:1784
|
0.013x |
|
Federal Mogul Izmit Piston ve Pim Uretim Tesisleri AS
IS:FMIZP
|
0.067x |
|
Raute Oyj
HE:RAUTE
|
-0.095x |
|
La Kaffa International Co Ltd
TWO:2732
|
0.106x |
Annual Cash Flow Conversion Efficiency for NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see NeOnc Technologies Holdings, Inc. Common market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-17.51 Million | $-20.36 Million | 1.163x | +51.95% |
| 2024-12-31 | $-5.50 Million | $-4.21 Million | 0.765x | +469.55% |
| 2023-12-31 | $-13.99 Million | $-1.88 Million | 0.134x | -75.99% |
| 2022-12-31 | $-1.58 Million | $-881.74K | 0.560x | +269.14% |
| 2021-12-31 | $-2.62 Million | $-396.69K | 0.152x | -- |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical… Read more